Despite the continuous deployment of advanced treatment strategies, most disseminated
cancers remain fatal. Like species evolution, cancer is subject to the evolutionary processes …

Cancer resistance evolution was presumed to result from either a pre-existing or acquired
mutation that survives treatment, re-populating the tumour following therapy. However, it …

Many highly effective cancer drugs are available for the treatment of solid tumors but
resistance almost invariably develops. The ability of cancers to acquire drug resistance by …

When metastatic cancers are challenged with targeted agents almost invariably a subset of
cells insensitive to the drug emerges. As a result, in most instances, targeted therapies are …

Colorectal cancer (CRC) arises by a continuous process of genetic diversification and clonal
evolution. Multiple genes and pathways have a role in tumor initiation and progression. The …

Colorectal cancer (CRC) is one of the most common cancers and one of the leading causes
of cancer related deaths worldwide. CRC is a heterogeneous disease where there can be …

Despite the continuous deployment of new treatment strategies and agents over many
decades, most disseminated cancers remain fatal. Cancer cells, through their access to the …

Many effective drugs for metastatic and/or advanced-stage cancers have been developed
over the past decade, although the evolution of resistance remains the major barrier to …

Despite continuous deployment of new treatment strategies and agents over many decades,
most disseminated cancers remain fatal. Cancer cells, through their access to the vast …

Intratumoral heterogeneity including genetic and nongenetic mechanisms refers to
biological differences amongst malignant cells originated within the same tumor. Both, cell …